mProX™ Human IL3RA Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

IL3RA, also known as interleukin-3 receptor alpha, has been studied in various applications. In one study, IL3RA was identified as one of the immunological genes that are elevated in breast cancer patients with doxorubicin-induced cardiotoxicity. These immune-related genes were found to be associated with pathways involved in immune responses and cardiac function. Additionally, IL3RA and other immune-related genes were found to be significantly associated with poor survival prognosis in breast cancer patients and showed diagnostic efficacy in patients with breast cancer and heart failure. In another study, IL3RA was investigated in the context of acute myeloid leukemia (AML) immunotherapy. Epitope editing of donor hematopoietic stem/progenitor cells (HSPCs) using IL3RA and other genes enabled the targeting of essential genes for leukemia survival, reducing the risk of tumor immune escape. This approach showed resistance of epitope-edited hematopoiesis to chimeric antigen receptor (CAR) T cell treatment and eradication of AML xenografts. IL3RA was also found to be involved in the assembly of eukaryotic initiation factor 2 (eIF2), a key factor in protein synthesis and regulation. Mutations in IL3RA were associated with MEHMO syndrome, an X-linked intellectual disability. The structure of IL3RA bound to eIF2 was determined, providing insights into its mechanism of action. Finally, IL3RA was studied in the context of melanoma liver metastasis. Gene expression analysis revealed differential expression of IL3RA and other chemokine/cytokine receptors in invasive and non-invasive melanoma cell lines. Overexpression of IL3RA was also observed in primary melanoma tissues with liver metastasis. These findings suggest that IL3RA may play a role in organ-specific metastasis of melanoma cells to the liver. Overall, IL3RA has been implicated in various biological processes and may have potential applications in cancer research and immunotherapy.